Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 6.42%
As of Tuesday, November 17, Avalyn Pharma Inc.’s AVLN share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Rosalio Madrigal
Michael Rose
| Share Statistics | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,243.0 | $436.9 | 49% |
|
| Shares Out (Mil) | 44.4 | 46.5 | 44% |
|
| Institutional Ownership | na | 82.2% | na |
|
| Float (Mil) | 29.9 | 47.7 | 36% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 517 | 339 | 57% |
|
| Price Change (52-week) |
na | 52.1% | na |
|
| Growth | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.6% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.720) | ($2.690) | ($2.580) | |
| Month Ago EPS | ($0.720) | ($2.690) | ($2.580) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | na | ($1.940) | ($1.900) | |
| Year/Year Chg | 7.6% | (96.9%) | (96.9%) | |
| Financials | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $289 | na |
|
| Net Income (TTM) (Mil) | ($109) | ($11) | 10% |
|
| EPS (TTM) | ($5.687) | ($0.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($106) | ($7) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $59 | $1 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $6 | 31% |
|
| Enterprise Value (Q1) (Mil) | $978 | $331 | 41% |
|
| Valuation | AVLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.35 | 2.15 | 72% |
|
| P/E | na | 24.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (54.8%) | (23.3%) | 10% |
|
| ROE | (59.1%) | (24.7%) | 14% |
|
| Liabilities to Assets | 7.3% | 31.8% | 4% |
|
| F-Score | 1 | 3 | na |
|
Avalyn Pharma Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors